To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)
← catalyst calendarSponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
200actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-26 | actual | When the study began enrolling |
| Primary completion | 2025-08-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-05 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Biological: CT-P6 SC
- Biological: EU-Approved Herceptin SC
Primary outcomes
what the primary-completion date above is the date OFDemonstrate PK similarity
measured Up to Day 64
Demonstrate PK similarity
measured Up to Day 64
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed